Skip to content
POCI

Precision Optics Corporation, Inc.

Precision Optics Corporation, Inc. Q4 FY2025 earnings call

September 29, 2025 · fiscal period ended 2025-06

EPS · actual vs est

$-0.18 /

Revenue · actual vs est

$6.2M /
Ask about this call

Summary

Generated 2025-09-29

Management highlights

  • Fourth quarter revenue was the highest in the company's history, with an annualized run rate of ~$25 million. - Two major programs transitioned from development to production, driving revenue. - Addressing gross margin challenges by improving yields, fixture/processes, and tariff reimbursement. - Invested in facilities by moving headquarters to Littleton, MA and South Portland, ME. - Hired manufacturing/quality engineers and a new COO, Joe Traut, with industry experience.
View in transcript ↓

Segment performance

The fourth quarter revenue was $6.2 million, with an annualized run rate of approximately $25 million. The systems manufacturing business is expected to grow over 75% in fiscal 2026. The aerospace program had Q4 revenue of just under $2 million, with a backlog of nearly $9 million and a mid-30% gross margin range. The single-use cystoscope had Q4 revenue of nearly $800,000, continuing the revenue increase trend. Product development is recovering, expected to increase from $4.9 million in 2025 to $5.6 million in 2026. Micro-optics labs revenue dropped from $2.1 million in 2025 to $1.3 million in 2026 due to timing. Ross Optical is expected to be flat at $3.7 million to $3.8 million.

View in transcript ↓

Guidance

  • Fiscal 2026 revenue expected to be ~$25 million, a >30% increase from 2025 ($19 million). - Gross margin expected to be ~30% in 2026, with improvement in the second half. - Expect adjusted EBITDA of ~$0.5 million positive in 2026.
View in transcript ↓

Risks

  • Gross margin challenges due to yield issues, labor touch time, and tariffs. - Uncertainty regarding tariff reimbursement agreements. - Start-up challenges with new production lines, like the single-use cystoscope program.
View in transcript ↓

Q&A highlights

Q: How to square guidance with revenue trends?

A: Conservative guidance due to timing of orders and pass-through capital costs.

Q: What's the status of tariff reimbursement?

A: Verbal agreements, need to document.

Q: How does the medical program cost reimbursement work?

A: Open book pricing, negotiated short-term price increase, aiming for original margins.

Q: Impact of engineering resources on production orders?

A: Engineers working on other programs, pipeline has 6-8 programs, 3 in verification/validation for production.

Q: Details on the second single-use program?

A: Ramping slowly, using cystoscope lessons, customer doubled forecast.

Q: Gross margin back half weighting?

A: Strengthening in back half due to cystoscope line work and aerospace ramp.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$-0.18$-0.23
Revenue$6.2M$4.7M

Transcript

September 29, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.